In contrast, another study found that PSMA-targeted CAR T-cells engineered to co-express an IL-23-targeting monoclonal antibody (mAb) led to eradication of prostate cancer in a murine model, suggesting that IL-23 blockade, not supplementation, may be beneficial in some contexts (57). The gene discussed is FOLH1; the disease is prostate cancer.